glp 1 prostate cancer GLP-1 Agonists: Dual Benefits for Diabetes and GLP-1s appear to cut cancer
Description
This occurs because the appetite-suppressing effects and delayed gastric emptying cease, leading to increased hunger and food intake returning to pre-treatment levels
2025: FDA expanded indication oral semaglutide now approved to reduce major cardiovascular events (MACE) in adults with T2DM at high CV risk
The trial was overseen and sponsored by Novo Nordisk
off-label microdosing is generally unsupported within NHS practice
